person
Olaposi Y.
- Country
- Germany
- Department
- Klinik für Innere Medizin II Abteilung Hämatologie und Internistische Onkologie
Research Overview
assignment
13
Clinical Trials ·
- Phase 3 Randomized Study of JNJ-79635322 Versus Teclistamab in Relapsed or Refractory Multiple Myeloma After Prior PI, IMiD, and Anti-CD38 Therapy
- A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2
- Randomized Phase II Study of Teclistamab + Daratumumab‑Lenalidomide‑Dexamethasone (Tec‑DRd) vs Daratumumab‑Lenalidomide‑Dexamethasone (DVRd) in Transplant‑Eligible NDMM
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
190
Sites with multiple studies
Has run more than one trial at 190 of 364 partner sites.
Specializations
Multiple Myeloma Treatment Specialization
This investigator demonstrates extensive expertise in treating multiple myeloma, with particular focus on both newly diagnosed cases and relapsed/refractory disease states.
- Newly Diagnosed Multiple Myeloma (NDMM)
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Transplant-Ineligible Multiple Myeloma
Therapeutic Approaches
The investigator's work encompasses various therapeutic modalities in hematologic oncology, particularly focusing on novel combination treatments.
- Maintenance Therapy Development
- Combination Treatment Strategies
- Post-Transplant Therapeutic Management
Treatment Innovation
The investigator works with novel therapeutic agents and emerging treatment approaches in multiple myeloma care.
- Monoclonal Antibody Therapies
- Novel Drug Combinations
- Alternative Administration Routes
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.